Aluminium Interference in the Treatment of Haemodialysis Patients with Recombinant Human Erythropoietin

In nine chronic haemodialysis patients a desferrioxamine (DFO) load test (40 mg/kg body-weight) was performed1 year after the beginning of treatment with recombinant human erythropoietin (rHuEpo). The patients were then divided intotwo groups. Group A comprised five patients with a greater mean alum...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nephrology, dialysis, transplantation dialysis, transplantation, 1990, Vol.5 (6), p.441-443
Hauptverfasser:	Casati, S., Castelnovo, Claudia, Campise, Mariarosaria, Ponticelli, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aluminium Aluminum - blood Anaemia Anemia - drug therapy Biological and medical sciences Deferoxamine - pharmacology Desferrioxamine Erythropoietin - therapeutic use Haemodialysis Humans Medical sciences Middle Aged Pharmacology. Drug treatments Recombinant human erythropoietin (rHuEpo) Recombinant Proteins - therapeutic use Renal Dialysis Urinary system
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!